Abstract:Age-related macular degeneration (AMD) is a leading cause of vision loss and irreversible blindness globally, highlighting the need for novel treatments to prevent or delay its progression. 1 Wang and colleagues 2 investigated whether pharmacologic treatments for dementia (which may have shared pathophysiological processes with AMD) are associated with incident AMD using 2 UK primary care records databases: Clinical Practice Research Datalink GOLD and Clinical Practice Research Datalink Aurum. They included individuals aged 40 years or older with a preexisting diagnosis of dementia who had a record of pharmacologic treatments for dementia. The authors separately compared memantine and donepezil with other standard first-line dementia drugs (rivastigmine and galantamine). Based on the results of competing-risks regression models, with death as the competing event, the authors found no evidence of a protective association between memantine or donepezil and AMD diagnosis. The findings by Wang and colleagues 2 contradict recent findings of no association between dementia medications and incident AMD. Sutton and colleagues 3 conducted a retrospective cohort study that included patients aged 55 to 80 years with a diagnosis of Alzheimer disease and no preexisting diagnosis of AMD, using data from the US Department of Veterans Affairs. They showed that in propensity score–matched Cox proportional hazards regression models, each additional year of acetylcholinesterase inhibitor treatment (donepezil, rivastigmine, and galantamine) was associated with a 6% lower hazard of AMD compared with untreated patients. In another study by Wang and colleagues, 4 the authors conducted an exploratory drug-screening study for drug exposures that were more commonly observed among older adults without progression to neovascular AMD compared with their counterparts using 2 health care claims databases: Medicare and IBM MarketScan Research Database. They found that dementia drugs, including memantine and donepezil, were more commonly used among older adults without progression to AMD, suggesting that they may prevent or delay progression to advanced AMD. Given the observational nature of the study and the use of billing codes, it is possible that residual confounding affected the findings. One possible explanation is that the observed findings may reflect the efficacy of dementia medications on cognitive function rather than on AMD. Medications with lower cognitive benefits may result in less health care engagement and, consequently, fewer AMD diagnoses, as individuals with dementia may be less likely to undergo vision screening or report visual symptoms. 5 Using data from the English National Health Service, Keenan and colleagues 5 concluded that patients with dementia are less likely to receive AMD treatment. Another possible explanation may be due to differences in genetic risk factors. Previous work by Rasmussen and colleagues 6 showed that structural variations in apolipoprotein ε, a major apolipoprotein in the central nervous system and lipid metabolism, are associated with the risk of AMD. Importantly, they showed a protective association of the ε4 allele with AMD. Because patients with the apolipoprotein ε4 allele are more likely progress to more severe stages of dementia and therefore are more likely to be treated with dementia medications, 7 the presence of the ε4 allele may have confounded the lower risk of incident AMD observed among patients who received dementia medications compared with their counterparts who did not receive treatment. Overall, the current evidence supporting dementia medications for AMD has remained largely inconsistent and unreliable. The findings presented by Wang and colleagues 2 demonstrating no evidence of a protective association between dementia medications and AMD diagnosis are more plausible than prior work, although further research is needed to explore any possible protective association of dementia medications with the development or progression of AMD and to determine whether findings support a randomized clinical trial. Published: October 24, 2024. doi:10.1001/jamanetworkopen.2024.41172 Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Almidani L et al. JAMA Network Open . Corresponding Author: Louay Almidani, MD, MSc, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD 21287 (lalmida1@jhu.edu). Conflict of Interest Disclosures: None reported.

Acetylcholinesterase Inhibitors, AMD, and Alzheimer Disease—Reply

Alzheimer Disease Treatment With Acetylcholinesterase Inhibitors and Incident AMD

Acetyl-cholinesterase-inhibitors reconsidered. A narrative review of post-marketing studies on Alzheimer's disease

Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation

Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Are Irreversible Inhibitors the Future?

Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?

The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

Brain cholinesterases: III. Future perspectives of AD research and clinical practice

Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease

Structural and molecular features of acetylcholinesterase targeting small molecules: Leveraging in-silico tools to combat Alzheimer's disease

Reply to: Challenges to identifying risk versus protective factors in Alzheimer's disease

Acetylcholinesterase inhibition of Alzheimer’s disease: identification of potential phytochemicals and designing more effective derivatives to manage disease condition

A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer’s disease

Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer's disease by docking, scoring and de novo evolution

Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease

A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase

Dementia Drugs and Age-Related Macular Degeneration

Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

The value of cholinesterase inhibitors for improving neuropsychiatric and functional assessment scores in patients with alzheimer disease: a systematic review and meta-analysis of on placebo-controlled RCTs

Factors Associated With Deprescribing Acetylcholinesterase Inhibitors in Older Nursing Home Residents With Severe Dementia

In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer's Disease